

IN THE CLAIMS

Please cancel claims 2 and 14-17, add claims 18 and 19, and amend the claims as shown below.

1. (Currently Amended) A substantially purified nucleic acid encoding gene ~~coding for~~ a pentapeptide having an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1) and a molecular weight of 570.959, wherein the C-terminal is amidated.

2. (Canceled)

3. (Currently Amended) The ~~gene~~ substantially purified nucleic acid as set forth in claim 1 ~~or 2~~, wherein the pentapeptide is ~~derived~~ obtained from pre-larvae of *Antheraea yamamai*.

4. (Previously Presented) A dormancy-control pentapeptide having an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1), a molecular weight of 570.959 and dormancy-control activity, wherein the C-terminal is amidated.

5. (Currently Amended) The dormancy-control pentapeptide as set forth in claim 4, wherein the dormancy-control pentapeptide is ~~derived~~ obtained from pre-larvae of *Antheraea yamamai*.

6. (Previously Presented) A method for preparing a dormancy-control pentapeptide, comprising the steps of

adding an acid-methanol solution consisting of methanol: water: acetic acid to pulverized pre-larvae of an insect;
triturating the resulting mixture;
centrifuging the mixture; and
subjecting the resulting supernatant to reverse phase high performance liquid chromatography and mixing-separation mode high performance liquid chromatography to give a dormancy-control pentapeptide, which has an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1) and a molecular weight of 570.959, wherein the C-terminal is amidated.

7. (Currently Amended) A ~~biological cell-control agent~~ composition comprising a physiologically acceptable carrier and, as an effective component, a pentapeptide having an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1), a molecular weight of 570.959, wherein the C-terminal is amidated.

8. (Currently Amended) The ~~biological cell-control agent~~ composition as set forth in claim 7, which is a cancer cell-control ~~agent~~ composition.

9. (Currently Amended) The ~~biological cell-control agent~~ composition as set forth in claim 7 or 8, wherein the pentapeptide is ~~derived~~ obtained from pre-larvae of *Antheraea yamamai*.

10. (Currently Amended) A ~~biological cell-control agent~~ composition comprising a physiologically acceptable carrier and, as an effective component, a tetrapeptide having an amino acid sequence of Ile-Leu-Arg-Gly (SEQ ID NO:2) and a molecular weight of 456.58, wherein the C-terminal is amidated.

11. (Currently Amended) The ~~biological cell-control agent~~ composition as set forth in claim 10, which is a cancer cell-control composition agent.

12. (Currently Amended) The ~~biological cell-control agent~~ composition as set forth in claim 10 or 11, wherein the tetrapeptide is ~~derived~~ obtained from pre-larvae of *Antheraea yamamai*.

13. (Currently Amended) A ~~dormancy-control~~ pentapeptide having an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1) ~~and dormancy-control activity~~.

14-17. (Canceled)

18. (New) A tetrapeptide having an amino acid sequence of Ile-Leu-Arg-Gly (SEQ ID NO:2).

19. (New) A tetrapeptide having an amino acid sequence of Ile-Leu-Arg-Gly (SEQ ID NO:2), wherein the C-terminal is amidated.